Coronavirus infection
Conditions
Interventions
Hyperimmune plasma anti-SARS-CoV-2
20 patients will be included and will be compared with historical controls, that were admitted before the start of the current study
Biological/vaccine
Sponsors
Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti
Paulo Niemeyer State Brain Institute
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age > or equal to 18 years; Severe or critical-19 COVID-19; Length of stay < 3 days; Laboratory confirmation of COVID-19 by detection of the viral genome in respiratory secretions, collected by swab; Signature, by the patient or a relative, of the informed consent form
Exclusion criteria
Exclusion criteria: Allergic reactions prior to plasma transfusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Temporal improvement in inflammatory biomarkers and organ dysfunction scores during ICU admission, measured by the daily reduction in 10% of biomarkers in plasma and respiratory secretions, per day for 14 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of 10% in mechanical ventilations days, measured by ventilation-free days during the first 14 days ;Reduction of 5% in in-hospital mortality, measured by the frequency of deaths during hospital admission ;Reduction of 10% in ICU length of stay, measured by days of ICU and hospital admission | — |
Countries
Brazil
Contacts
Public ContactPedro ;Pedro Kurtz;Kurtz
Instituto Estadual do Cérebro Paulo Niemeyer ;Instituto Estadual do Cérebro Paulo Niemeyer
Outcome results
None listed